[1] Ten Hagen KG, Fritz TA, Tabak LA, et al. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases[J]. Glycobiologyvol, 2003, 13(1): 1R-16R.
[2] Huang MJ, Hu RH, Chou CH, et al. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling[J]. Oncotarget, 2015, 6(8):5650-5665.
[3] Guo JM, Chen HL, Wang GM, et al. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer[J]. Oncology, 2004, 67(34):271-276.
[4] Gu C, Oyama T, Osaki T, et al. Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence[J]. Br J Cancer, 2004, 90(2):436-442.
[5] Wang ZQ, Bachvarova M, Morin C, et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation[J]. Oncotarget, 2014, 5(2):544-560.
[6] Lina MC, Huang MJ, Liu CH, et al. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity[J]. Oral Oncology, 2014, 50(5):478-484.
[7] Gao Y, Liu Z, Feng J, et al. Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma[J]. Oncol Lett, 2013, 5(1):113-116.
[8] Li Z, Yamada S, Wu Y, et al. Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection[J]. Oncotarget, 2016, 7(34): 54463-54473
[9] Berois N, Mazal D, Ubillos L, et al. UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker[J]. J Histochem Cytochem, 2006, 54(3): 317-328.
[10] He H, Shen Z, Zhang H, et al. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer[J]. Br J Cancer, 2014, 110(8): 2021-2029.
|